Abbvie Inc.

Abbott Laboratories Corporation

Other

Ligand Pharmaceuticals, Inc.

Michael E Kort

Philip R Kym

Arthur Gomtsyan

Jerome F Daanen

Eric A Voight

Erol K Bayburt

Robert G Schmidt

Richard J Perner

Stanley DiDomenico

Michael J Coghlan

William A Carroll

Anil Vasudevan

Gregory A Gfesser

Meena V Patel

Tammie K Jinkerson

Jun Chen

Michael J Dart

Kevin R Woller

Irene I Drizin

Huaqing Liu

Mark A Matulenko

Bruce Clapham

Phil B Cox

James Patrick Edwards

Todd Kevin Jones

Robert J Altenbach

Lawrence A Black

Teodozyj Kolasa

Andrew O Stewart

John R Koenig

Derek W Nelson

Jeffrey J Rohde

Anwer Basha

Ryan G Keddy

Catherine M McCarty

Heath A McDonald

Marlon D Cowart

John K Pratt

David A DeGoey

Bo Liu

Jimmie L Moore

Marc J Scanio

Mark W Holladay

Andrew Bogdan

Brian D Wakefield

Henry Q Zhang

Anurupa Shrestha

Hillary M Peltier

Robert J Gregg

Alan X Wang

Konstantinos A Agrios

Steven Elmore

Chih-hung Lee

Clara I Villamil

Arturo Perez-Medrano

Sridhar Peddi

Murali Gopalakrishnan

Adrian Hobson

Brian S Brown

James P Sullivan

Martine Barth

Hao Bai

Fatima Z Basha

Maria A Argiriadi

Eric C Breinlinger

Peggy Huang

Kathleen Mortell

Kevin Patrick Cusack

Jorge D Brioni

John K Lynch

Lin Yi

Jerome Amaudrut

J&uuml;rgen Dinges

Yiyuan Chen

Dominique Potin

Arturo Perez Medrano

John F Kincaid

Rui Tang

Steven W Elmore

Jérôme Amaudrut

Olivia Poupardin

Laurent Mounier

Pamela S Puttfarcken

Arthur R Gomtsyan

The invention provides compounds of Formula (I) pharmaceutically acceptable salts, thereof wherein the variable are defined herein. The compounds of the invention are useful for treating immunological conditions.

Nuclear receptor modulators

Compounds of formula (I) and pharmaceutically acceptable salts, esters, amides, or radiolabelled forms thereof, wherein R, R, and Rare as defined in the specification, are useful in treating conditions or disorders prevented by or ameliorated by voltage-gated sodium channels, e.g., Na1.7 and/or Na1.8. Methods for making the compounds are disclosed. Also disclosed are pharmaceutical compositions of compounds of formula (I), and methods for using such compounds and compositions.

6-heteroaryloxy- or 6-aryloxy-quinoline-2-carboxamides and method of use

Compounds of formula (I) wherein R, R, R, and Y are defined in the description are TRPA1 antagonists. Compositions comprising such compounds and methods for treating conditions and disorders using such compounds and compositions are also disclosed.

TRPA1 antagonists

Disclosed herein are modulators of TRPV3 of formula (I) wherein G, X, X, X, X, X, G, Z, R, R, u, and p are as defined in the specification. Compositions comprising such compounds and methods for treating conditions and disorders using such compounds and compositions are also presented.

TRPV3 modulators

Compounds of formula (I) wherein R, R, R, m, and Y are defined in the specification are TRPA1 antagonists. Compositions comprising such compounds and methods for treating conditions and disorders using such compounds and compositions are also disclosed.

Disclosed herein are modulators of TRPV3 of formula (I) wherein X, X, R, R, R, and n are as defined in the specification. Compositions comprising such compounds and methods for treating conditions and disorders using such compounds and compositions are also presented.

Disclosed herein are compounds of formula (I): or pharmaceutically acceptable salts thereof, wherein X, L, R, R, G, Z, A, m, n, and p are as defined in the specification. Compositions comprising such compounds and methods for treating conditions and disorders using such compounds and compositions are also disclosed.

TRPV1 antagonists

Disclosed herein are compounds of formula (I): or pharmaceutically acceptable salts thereof, wherein X, L, R, R, R, A, m, n, p, q, s, and positions a and b are as defined in the specification. Compositions comprising such compounds and methods for treating conditions and disorders using such compounds and compositions are also disclosed.

Disclosed herein are compounds of formula (I) or pharmaceutically acceptable salts, solvates, or combinations thereof, wherein X, X, X, X, J, K, L, X, X, R, G, and m are defined in the specification. Compositions comprising such compounds and methods for treating conditions and disorders using such compounds and compositions are also disclosed.

Disclosed herein are compounds of formula (I) or pharmaceutically acceptable salts, prodrugs, or combinations thereof, wherein X, L, R, R, R, R, R, A, m, n, p, q, and r are defined in the specification. Compositions comprising such compounds and methods for treating conditions and disorders using such compounds and compositions are also disclosed.

Disclosed herein are modulators of TRPV3 of Formula (I) wherein p is 1, 2, 3, or 4, and G, X, X, X, X, X, G, Z, R, R, and u are as defined in the specification. Compositions comprising such compounds and methods for treating conditions and disorders using such compounds and compositions are also presented.

Disclosed herein are modulators of TRPV3 of formula (II): wherein G, X, X, X, X, X, G, R, R, and u are as defined in the specification. Compositions comprising such compounds and methods for treating conditions and disorders using such compounds and compositions are also presented.

Disclosed herein are compounds of formula (I), or pharmaceutically acceptable salts, solvates, prodrugs, salts of prodrugs, or combinations thereof, wherein R, R, R, R, and m are defined in the specification. Compositions comprising such compounds and methods for treating conditions and disorders using such compounds and compositions are also disclosed.

Growing community of inventors

Lake Bluff, IL, United States of America

Michael E Kort